uric acid and imatinib mesylate

uric acid has been researched along with imatinib mesylate in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	1 (25.00)	2.80

Authors

Authors	Studies
Bonmort, M; Chaperot, L; Chaput, N; Flament, C; Ménard, C; Mignot, G; Plumas, J; Terme, M; Ullrich, E; Zitvogel, L	1
Akinci, S; Atalay, HV; Basturk, A; Dilek, I; Hacibekiroglu, T	1
Balbino, B; Contag, CH; Galli, SJ; Gaudenzio, N; Kang, D; Raghu, H; Reber, LL; Robinson, WH; Rogalla, S; Sensarn, S; Sibilano, R; Sokolove, J; Starkl, P; Tsai, M	1
Edao, A; Hailemariam, TS; Kinde, S; Mehdi, M; Seifu, D	1

Reviews

1 review(s) available for uric acid and imatinib mesylate

Article	Year
Dendritic cells and innate defense against tumor cells. Cytokine & growth factor reviews, 2008, Volume: 19, Issue:1 Topics: Apoptosis; Benzamides; Biomarkers, Tumor; Cancer Vaccines; CpG Islands; Cytokines; Dendritic Cells; Fas Ligand Protein; Granulocyte-Macrophage Colony-Stimulating Factor; HMGB1 Protein; Humans; Imatinib Mesylate; Immunity, Innate; Interferon Type I; Interferon-gamma; Interferons; Interleukin-15; Killer Cells, Natural; Neoplasms; Oligodeoxyribonucleotides; Piperazines; Pyrimidines; Receptor Cross-Talk; T-Lymphocytes, Helper-Inducer; Uric Acid	2008

Article

Year

Dendritic cells and innate defense against tumor cells.

Cytokine & growth factor reviews, 2008, Volume: 19, Issue:1

Topics: Apoptosis; Benzamides; Biomarkers, Tumor; Cancer Vaccines; CpG Islands; Cytokines; Dendritic Cells; Fas Ligand Protein; Granulocyte-Macrophage Colony-Stimulating Factor; HMGB1 Protein; Humans; Imatinib Mesylate; Immunity, Innate; Interferon Type I; Interferon-gamma; Interferons; Interleukin-15; Killer Cells, Natural; Neoplasms; Oligodeoxyribonucleotides; Piperazines; Pyrimidines; Receptor Cross-Talk; T-Lymphocytes, Helper-Inducer; Uric Acid

2008

Other Studies

3 other study(ies) available for uric acid and imatinib mesylate

Article	Year
Is there any protective effect on organs upon higher uric acid level in tumor lysis syndrome? Renal failure, 2011, Volume: 33, Issue:4 Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Tumor Lysis Syndrome; Uric Acid	2011
The tyrosine kinase inhibitor imatinib mesylate suppresses uric acid crystal-induced acute gouty arthritis in mice. PloS one, 2017, Volume: 12, Issue:10 Topics: Animals; Arthritis, Gouty; Crystallization; Imatinib Mesylate; Injections, Intraperitoneal; Mice; Mice, Inbred C57BL; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Uric Acid	2017
BCR-ABL Transcript Level as Compared to LDH and Uric Acid Among Chronic Myeloid Leukemic Patients. Recent patents on anti-cancer drug discovery, 2021, Volume: 16, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Developing Countries; Female; Fusion Proteins, bcr-abl; Health Services Accessibility; Humans; Hydroxyurea; Imatinib Mesylate; L-Lactate Dehydrogenase; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Pyrimidines; Real-Time Polymerase Chain Reaction; RNA, Messenger; Uric Acid; Young Adult	2021